{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:39Z","timestamp":1792123659535,"version":"4.4.0"},"reference-count":84,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP20K09824"],"award-info":[{"award-number":["JP20K09824"]}]},{"name":"JSPS KAKENHI","award":["JP25K02864"],"award-info":[{"award-number":["JP25K02864"]}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare of Japan","doi-asserted-by":"crossref","award":["22FC0201"],"award-info":[{"award-number":["22FC0201"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Japan Agency for Medical Research and Development, AMED","award":["23fk0108671h0001"],"award-info":[{"award-number":["23fk0108671h0001"]}]},{"name":"Japan Agency for Medical Research and Development, AMED","award":["23fk0108672h0001"],"award-info":[{"award-number":["23fk0108672h0001"]}]},{"award":["23fk0108671h0001"],"award-info":[{"award-number":["23fk0108671h0001"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"award":["23fk0108672h0001"],"award-info":[{"award-number":["23fk0108672h0001"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["FY2023"],"award-info":[{"award-number":["FY2023"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"award":["FY2023"],"award-info":[{"award-number":["FY2023"]}],"id":[{"id":"https:\/\/ror.org\/02y123g31","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by restoring anti-tumor immunity, but immune activation can disrupt ocular immune homeostasis and induce ophthalmic immune-related adverse events (OirAEs). Although uncommon, OirAEs may involve nearly all ocular compartments and can cause irreversible visual impairment or interruption of effective anticancer therapy. The 2025 international consensus criteria now provide a standardized framework for defining and classifying OirAEs. This review integrates current evidence on ICI-associated ocular toxicity, with emphasis on tissue-specific immune mechanisms and their clinical implications. Blockade of the PD-1\/PD-L1 and CTLA-4 pathways may impair ocular immune privilege, expand autoreactive T-cell subsets, alter cytokine and chemokine networks, and amplify autoantibody-mediated retinal injury. These processes provide a plausible framework for understanding diverse phenotypes, including uveitis, ocular surface disease, optic neuritis, orbital inflammation, ocular myopathy, and retinopathy. We also outline a mechanism-informed management approach that balances visual preservation with maintenance of systemic anti-tumor immunity. Local corticosteroid therapy, cautious systemic immunosuppression, and selected steroid-sparing biologics should be individualized according to severity, anatomical involvement, and the oncologic context. Together, these insights support a consensus-based and mechanism-informed framework for recognizing and managing OirAEs while preserving systemic anti-tumor immunity.<\/jats:p>","DOI":"10.3390\/ijms27135944","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:50:33Z","timestamp":1782924633000},"page":"5944","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ophthalmic Immune-Related Adverse Events in Cancer Immunotherapy: Tissue-Specific Mechanisms, Clinical Phenotypes, and Consensus-Based Management"],"prefix":"10.3390","volume":"27","author":[{"given":"Yuan","family":"Zong","sequence":"first","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3124-1101","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1359-8198","authenticated-orcid":false,"given":"Yaru","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhen","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5070-3431","authenticated-orcid":false,"given":"Wendong","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Ohno-Matsui","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koju","family":"Kamoi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e20201979","DOI":"10.1084\/jem.20201979","article-title":"Immune checkpoint inhibitors","volume":"218","author":"Kroemer","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/sjopt.sjopt_296_23","article-title":"Immune checkpoint monoclonal antibody-related adverse effects in neuro-ophthalmology","volume":"38","author":"Ameri","year":"2024","journal-title":"Saudi J. Ophthalmol."},{"key":"ref_3","first-page":"9565205","article-title":"Outcome of Nivolumab-Induced Vogt-Koyanagi-Harada Disease-like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy","volume":"2023","author":"Nagai","year":"2023","journal-title":"Case Rep. Ophthalmol. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/CJI.0000000000000476","article-title":"Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab","volume":"46","author":"Huang","year":"2023","journal-title":"J. Immunother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.18240\/ijo.2022.04.19","article-title":"Immune checkpoint inhibitor-associated ophthalmic adverse events: Current understanding of its mechanisms, diagnosis, and management","volume":"15","author":"Zhou","year":"2022","journal-title":"Int. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ophtha.2020.05.003","article-title":"Immune Checkpoint Inhibitor-Associated Optic Neuritis","volume":"127","author":"Francis","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Seidel, J.A., Otsuka, A., and Kabashima, K. (2018). Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00086"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-022-01827-8","article-title":"Tremelimumab: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-015-0442-6","article-title":"Nivolumab: A Review in Advanced Melanoma","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40265-016-0543-x","article-title":"Pembrolizumab: A Review in Advanced Melanoma","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40265-020-01302-2","article-title":"Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients with Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial","volume":"6","author":"Andre","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.annonc.2022.07.011","article-title":"First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin","volume":"33","author":"Iacovelli","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): A randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40265-022-01671-w","article-title":"Envafolimab: First Approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s43018-023-00578-z","article-title":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: Sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC","volume":"4","author":"Zhou","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update","volume":"41","author":"Seth","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Brown, A.C., Quiroz, J., Parikh, D.A., Li, Y., Ritzer, L., Rosen, R., and Deobhakta, A. (2024). Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis. BMC Ophthalmol., 24.","DOI":"10.1186\/s12886-024-03575-7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/08820538.2024.2433636","article-title":"Ocular Immune-Related Adverse Events Associated with PD-1 Inhibitors: From Molecular Mechanisms to Clinical Management","volume":"40","author":"Gong","year":"2025","journal-title":"Semin. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.preteyeres.2019.04.002","article-title":"Immune privilege in corneal transplantation","volume":"72","author":"Hori","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1167\/iovs.08-2397","article-title":"PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation","volume":"50","author":"Yang","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1167\/iovs.66.14.53","article-title":"Can Immune Checkpoint Modulation Redefine Ocular Immunotherapy? Emerging Mechanisms, Challenges, and Translational Opportunities-A Comprehensive Review","volume":"66","author":"Chen","year":"2025","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrd.2018.148","article-title":"Regulatory T cells in the treatment of disease","volume":"17","author":"Sharabi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.iac.2021.12.006","article-title":"Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models","volume":"42","author":"Park","year":"2022","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e012350","DOI":"10.1136\/jitc-2025-012350","article-title":"Clonally expanded effector CD4(+) cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy","volume":"13","author":"Giguelay","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1158\/1078-0432.CCR-08-2424","article-title":"Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4","volume":"15","author":"Klein","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1080\/09273948.2019.1582785","article-title":"Intraocular Concentrations of Cytokines and Chemokines in a Unique Case of Nivolumab-Induced Uveitis","volume":"28","author":"Yoshida","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Xiao, J., Zhao, C., Cheng, G., Song, H., Zhang, Y., and Zhang, M. (2024). Multiple cytokine analysis of aqueous humor in uveitis with or without secondary glaucoma. BMC Ophthalmol., 24.","DOI":"10.1186\/s12886-024-03691-4"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9394(14)76622-X","article-title":"Paraneoplastic night blindness with malignant melanoma","volume":"106","author":"Berson","year":"1988","journal-title":"Am. J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1073\/pnas.92.20.9176","article-title":"Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy","volume":"92","author":"Polans","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","first-page":"e21709","article-title":"Anti-Programmed Death Ligand-1 Induced Acute Vision Loss in a Patient with Cancer-Associated Retinopathy","volume":"14","author":"Chauhan","year":"2022","journal-title":"Cureus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/jamaophthalmol.2016.2944","article-title":"Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated with Pembrolizumab","volume":"134","author":"Roberts","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/OTT.S65802","article-title":"Tremelimumab: Research and clinical development","volume":"9","author":"Ibarrondo","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41433-021-01676-x","article-title":"Paraneoplastic ocular syndrome: A pandora\u2019s box of underlying malignancies","volume":"36","author":"Sarkar","year":"2022","journal-title":"Eye"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): A comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: A systematic review","volume":"17","author":"Oweira","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis","volume":"30","author":"Bomze","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wu, K.Y., Yakobi, Y., Gueorguieva, D.D., and Mazerolle, \u00c9. (2024). Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review. Biomedicines, 12.","DOI":"10.3390\/biomedicines12112547"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kumar, V., Chaudhary, N., Garg, M., Floudas, C.S., Soni, P., and Chandra, A.B. (2017). Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front. Pharmacol., 8, Correction in Front. Pharmacol. 2017, 8, 311.","DOI":"10.3389\/fphar.2017.00049"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhou, L., and Wei, X. (2021). Ocular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Lung Cancer. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.701951"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.36401\/JIPO-22-14","article-title":"Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center","volume":"5","author":"Mazharuddin","year":"2022","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s00262-020-02635-3","article-title":"Factors associated with ocular adverse event after immune checkpoint inhibitor treatment","volume":"69","author":"Kim","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/bjophthalmol-2020-317060","article-title":"Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database","volume":"106","author":"Xia","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: The Mayo Clinic experience","volume":"105","author":"Fortes","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e011545","DOI":"10.1136\/jitc-2025-011545","article-title":"Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: A prospective pan-tumor cohort study","volume":"13","author":"Quandt","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.survophthal.2021.01.001","article-title":"Ocular side effects of checkpoint inhibitors","volume":"66","author":"Alba","year":"2021","journal-title":"Surv. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Iranzo, P., Callejo, A., Assaf, J.D., Molina, G., Lopez, D.E., Garcia-Illescas, D., Pardo, N., Navarro, A., Martinez-Marti, A., and Cedres, S. (2022). Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front. Med., 9.","DOI":"10.3389\/fmed.2022.875974"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ajo.2020.12.013","article-title":"Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment","volume":"224","author":"Braun","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.3747\/co.25.4047","article-title":"Predictors of immunotherapy-induced immune-related adverse events","volume":"25","author":"Kartolo","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e011049","DOI":"10.1136\/jitc-2024-011049","article-title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Chang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09273948.2020.1781902","article-title":"Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes","volume":"29","author":"Dow","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1080\/09273948.2020.1766082","article-title":"Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series","volume":"29","author":"Parikh","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1002\/phar.1839","article-title":"A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma","volume":"36","author":"Hanna","year":"2016","journal-title":"Pharmacotherapy"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12348-016-0082-3","article-title":"Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma","volume":"6","author":"Hahn","year":"2016","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/IIO.0000000000000434","article-title":"Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity","volume":"62","author":"Rali","year":"2022","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1080\/09273948.2021.1910850","article-title":"Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors","volume":"30","author":"Thurau","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ajo.2005.08.025","article-title":"Research criteria for the diagnosis of birdshot chorioretinopathy: Results of an international consensus conference","volume":"141","author":"Levinson","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/tjo.tjo_88_17","article-title":"Bilateral anterior uveitis after immunotherapy for malignant melanoma","volume":"8","author":"Chang","year":"2018","journal-title":"Taiwan J. Ophthalmol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Gan, L., Chen, H., Liu, X., and Zhang, L. (2023). Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1130238"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"368","DOI":"10.18502\/jovr.v19i3.15047","article-title":"Immune Checkpoints and Graves\u2019 Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review","volume":"19","author":"Souri","year":"2024","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"viii217","DOI":"10.1093\/neuonc\/noae165.0855","article-title":"NCMP-02. Utility of Ice Pack Test for Early Recognition of Immune Checkpoint Inhibitor Mediated Ocular Weakness","volume":"26","author":"Zahid","year":"2024","journal-title":"Neuro-Oncology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic Immune-Related Adverse Events Following Adjuvant Anti\u2013PD-1 Therapy for High-risk Resected Melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/2474126419886154","article-title":"A Case of Melanoma-Associated Retinopathy, Uveitis, and Optic Neuritis Associated with Pembrolizumab, Managed with Topical, Intravitreal, and Intravenous Steroids","volume":"4","author":"Xie","year":"2020","journal-title":"J. Vitreoretin. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10633-020-09795-8","article-title":"Melanoma-associated retinopathy during pembrolizumab treatment probably controlled by intravitreal injections of dexamethasone","volume":"142","author":"Poujade","year":"2021","journal-title":"Doc. Ophthalmol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e00730","DOI":"10.1002\/rcr2.730","article-title":"Complete response in a patient with lung cancer suffering from three pembrolizumab-induced immune-related adverse events including retinal vasculitis","volume":"9","author":"Mimura","year":"2021","journal-title":"Respirol. Case Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"kead104.069","DOI":"10.1093\/rheumatology\/kead104.069","article-title":"P027 Immune checkpoint inhibitor associated vasculitis: A limitation to cancer therapy","volume":"62","author":"Au","year":"2023","journal-title":"Rheumatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/bjo-2025-327349","article-title":"Cyclosporine in uveitis: A game changer or a risky choice? A systematic review and meta-analysis of its efficacy and safety","volume":"110","author":"Chen","year":"2025","journal-title":"Br. J. Ophthalmol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12348-024-00443-9","article-title":"Long-term effects of tocilizumab on retinal and choroidal inflammation in Birdshot uveitis","volume":"14","author":"Schulze","year":"2024","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10067-018-4007-4","article-title":"Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: Two cases report and literature review","volume":"37","author":"Leclercq","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrd2909","article-title":"Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond","volume":"11","author":"Hogarth","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wu, K.Y., Fujioka, J.K., Gholamian, T., Zaharia, M., and Tran, S.D. (2023). Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091241"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5944\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:46:55Z","timestamp":1783054015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":84,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27135944"],"URL":"https:\/\/doi.org\/10.3390\/ijms27135944","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}